^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Parsortix Liquid Biopsy

Company:
ANGLE
Type:
FDA Approved
Related tests:
Evidence

News

5d
Independent study of ovarian cancer CTCs harvested by the Parsortix system highlights potential to predict progression free survival for drug trials (ANGLE plc Press Release)
"ANGLE plc...is delighted to announce the publication of a study using the Parsortix® system to identify markers present in CTCs harvested from metastatic mutant-p53 platinum-resistant ovarian cancer (PROC) patients. The study was conducted as an offshoot of the European multi-centre GANNET53 Phase II clinical trial (NCT02012192) funded by the EU 7th Framework Programme (Grant agreement ID: 602602). The study investigated the efficacy of ganetespib in combination with paclitaxel vs. paclitaxel alone. Patients were enrolled across 12 clinical centres in Germany, Belgium, France, and Austria."
P2 data
|
Parsortix Liquid Biopsy
18d
New commercial agreement with large pharma (ANGLE plc Press Release)
"ANGLE plc...is delighted to announce that it has signed a supplier agreement to develop a Parsortix-based Androgen Receptor1 (AR) detection assay for use in prostate cancer studies. The supplier agreement reported here is with AstraZeneca...This follows an earlier agreement to develop a methodology for CTC micronuclei detection using the Company's DNA Damage Response (DDR) assay, announced on 24 April 2024."
Licensing / partnership
|
Parsortix Liquid Biopsy
26d
New commercial agreement with large pharma (ANGLE plc Press Release)
"ANGLE plc...has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response ('DDR') assay for the detection of micronuclei in CTCs as a measure of DDR."
Licensing / partnership
|
Parsortix Liquid Biopsy
1m
CTC HER2 assay being developed for HER2 targeted drugs and antibody drug conjugates presented at internationally renowned AACR Annual Meeting 2024 (ANGLE plc Press Release)
"ANGLE plc...announce its participation at the American Association for Cancer Research (AACR) Annual Meeting, San Diego, US between 5 to 10 April 2024...ANGLE is presenting a poster entitled the 'Development and analytical validation of a novel assay for HER2 assessment on circulating tumor cells harvested using the Parsortix® system and incorporating BioView imaging technologies'."
Clinical data
|
Parsortix Liquid Biopsy
2ms
Parsortix system and assays being showcased at a leading European Breast Cancer Conference (ANGLE plc Press Release)
"ANGLE plc...is pleased to announce its participation at the 14th European Breast Cancer Conference (EBCC) being held in Milan, Italy on 20 to 22 March 2024...ANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait HER2 assay"
Clinical data
|
Parsortix Liquid Biopsy • Portrait HER2 assay
3ms
Detection of PD-L1 mRNA expression in circulating tumor cells (CTCs) from patients with metastatic NSCLC, HNSCC and melanoma using a novel highly sensitive commercially available CE-IVD kit (AACR 2024)
The commercially available Oncolipsy PD-L1 kit can be used for the quantification of PD-L1 transcripts in CTCs. Expression of PD-L1 in size-based enriched CTCs can predict response to PD-1/PD-L1 blockade therapy.
Clinical • PD(L)-1 Biomarker • Circulating tumor cells • IO biomarker • Tumor cell • Metastases
|
PD-L1 (Programmed death ligand 1) • B2M (Beta-2-microglobulin) • KRT19 (Keratin 19)
|
PD-L1 expression
|
Parsortix Liquid Biopsy
3ms
Dissecting circulating tumor cells phenotype in a cohort of locally advanced non-small cell lung cancer patients undergoing neoadjuvant chemotherapy (AACR 2024)
Cisplatin-induced cell damage has been shown to activate the SDF-1/CXCR4 axis in preclinical models of NSCLC, resulting in the recruitment of a cell subset co-expressing the stemness marker CD133 and CXCR4 (SDF-1 receptor) at distant sites... Out of the 61 enrolled patients, 34 had available CTC data for analysis. In this population, DCR was 64.7%, and the ORR 29.4%. Surgery was performed in 14 pts (41.2%).
Clinical • Circulating tumor cells • Tumor cell • Metastases
|
CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CD133 expression
|
Parsortix Liquid Biopsy
|
cisplatin
3ms
Development and analytical validation of a novel assay for HER2 assessment on circulating tumor cells using Parsortix® isolation and BioView imaging technologies (AACR 2024)
The assay enables the identification of both HER2 protein and gene copy information from each target cell with minimal cell loss, with the potential for minimally invasive patient monitoring during treatment and better classification of patients who may qualify and benefit from HER2-targeted therapies. An added value of the assay is the practicality of utilizing preserved blood samples, allowing streamline batch shipping of clinical samples.
Circulating tumor cells • Tumor cell
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • HER-2 negative • HER-2 expression
|
Parsortix Liquid Biopsy • Portrait HER2 assay
3ms
Comparison of Different Circulating Tumour Cell (CTC) Enrichment Technologies in Patients with Resectable Lung Cancer (EACR-AACR 2024)
Our results show that the PR1 system can successfully capture CTCs from the blood of patients with resectable LC. Monitoring CTC counts post LC surgery may have prognostic relevance and could have an application in the clinical setting, but future research is required.
Clinical • Circulating tumor cells • Tumor cell
|
EPCAM (Epithelial cell adhesion molecule) • VIM (Vimentin)
|
Parsortix Liquid Biopsy
3ms
Circulating tumour cells (CTCs) correlate with markers of inflammatory response in metastatic breast cancer (EACR-AACR 2024)
HER2+ CTCs were also detected in tissue HER2- patients, indicating further investigations are warranted into the clinical significance of HER2+ CTCs. High CTC counts were associated with an increase in PLR, NLR and PAI-1 levels indicating that high CTC trafficking in MBC is associated with an altered inflammatory response which may aid in metastatic dissemination.
Circulating tumor cells • Tumor cell • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • KRT19 (Keratin 19)
|
HER-2 negative
|
CELLSEARCH® • Parsortix Liquid Biopsy
3ms
­­­DanioCTC: Analysis of circulating tumor cells from metastatic breast cancer patients in zebrafish xenografts (DKK 2024)
Successful xenografting of CTCs from a MBC patient revealed their primary localization in the head and trunk regions of zebrafish embryos. DanioCTC represents a major step forward in endeavors to study the dissemination of individual and rare patient-derived CTCs, thereby enhancing our understanding of metastatic breast cancer biology and facilitating the development of targeted interventions in MBC.
Clinical • Circulating tumor cells • Tumor cell • Metastases
|
Parsortix Liquid Biopsy
3ms
Prognostic Significance of Circulating Tumour Cells (CTCs) and Circulating Tumour DNA (ctDNA) in High-Grade Serous Ovarian Cancer (USCAP 2024)
We report that with the use of CTCID markers, single and clusters CTCs can be isolated from ovarian cancer patients with prognostic significance. CTCs isolated from the ovarian vein during surgery are indicative of precursor oligoclonal metastasizing HGSC. Actionable HGSC mutations were found in ctDNA, and may have clinical utility in predicting residual disease, monitoring treatment response, and prognosis in the adjuvant setting.
Circulating tumor cells • BRCA Biomarker • Circulating tumor DNA • Tumor cell
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • MUC16 (Mucin 16, Cell Surface Associated) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule)
|
TP53 mutation • KRAS mutation • BRCA1 mutation • MET mutation
|
Parsortix Liquid Biopsy
3ms
Longitudinal Enumeration of Circulating Tumour Cells in Epithelial Ovarian Cancer (USCAP 2024)
CTCs were detected across all assessed time points. Regular and dynamic liquid biopsies are essential to assess the clinical relevance of CTCs across the subtypes of EOC. Ongoing follow-up investigation within this patient cohort continues, and further longitudinal sampling is ongoing.
Circulating tumor cells • Tumor cell
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
Parsortix Liquid Biopsy
3ms
EARDIS: Proof-of-concept Study of Blood Markers of Tumor Dissemination in Patients With Versus Without Intestinal Polyps (clinicaltrials.gov)
P=N/A; N=60 --> 90 | Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Sep 2024 --> Feb 2025
Trial completion date • Trial primary completion date • Enrollment change
|
Parsortix Liquid Biopsy
3ms
Clinical • Circulating tumor cells • Tumor cell • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
Parsortix Liquid Biopsy
4ms
Review paper on molecular analysis of Parsortix CTC harvest highlights potential utility in precision oncology (ANGLE plc Press Release)
"ANGLE plc...is pleased to announce the publication of a peer-reviewed paper in a special issue of the journal - 'Current Issues in Molecular Biology' Special Issue: Advanced Solutions for Cancer Therapy...This peer-reviewed article brings together supporting evidence for the additional and complementary information that can be obtained from CTCs using the Parsortix® system, demonstrating the value of a dual analyte approach for both CTCs and ctDNA."
Review
|
Parsortix Liquid Biopsy
4ms
Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the Parsortix System. (PubMed, Curr Issues Mol Biol)
Herein, we review the literature in which the microfluidic, label-free Parsortix system is utilised for CTC capture, harvest and analysis, alongside the analysis of ctDNA from a single blood sample. This detailed summary of the literature demonstrates how these two analytes can provide complementary disease information.
Journal • Review • Circulating tumor cells • Circulating tumor DNA • Tumor cell
|
Parsortix Liquid Biopsy
4ms
Longitudinal detection of circulating tumour cells in serous and non-serous epithelial ovarian carcinomas (ESGO 2024)
Enumerating CTCs throughout treatment in EOC is imperative to assess their clinical significance. Ongoing follow-up and longitudinal sampling of this patient cohort continues.
Circulating tumor cells • Tumor cell
|
MUC16 (Mucin 16, Cell Surface Associated) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule)
|
Parsortix Liquid Biopsy
4ms
Proffered Paper: Prognostic significance of circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) in high-grade serous ovarian cancer (EACR-AACR 2024)
CTCs isolated from the ovarian vein during surgery are indicative of precursor oligoclonal metastasizing HGSC. Actionable HGSC mutations were found in ctDNA, and may have clinical utility in predicting residual disease, monitoring treatment response, and prognosis in the adjuvant setting.
Circulating tumor cells • BRCA Biomarker • Circulating tumor DNA • Tumor cell
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • MUC16 (Mucin 16, Cell Surface Associated) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule)
|
TP53 mutation • KRAS mutation • BRCA1 mutation • MET mutation
|
Parsortix Liquid Biopsy
4ms
Longitudinal detection of circulating tumour cells in epithelial ovarian cancer (EACR-AACR 2024)
Dynamic and frequent blood sampling is essential to assess the clinical significance of CTCs across the subtypes of EOC. Ongoing follow-up investigation within this patient cohort continues, and further longitudinal sampling is underway.
Circulating tumor cells • Tumor cell
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
Parsortix Liquid Biopsy
5ms
Breakthrough clinical results provide a unique insight into the progression of each patient's cancer (ANGLE plc Press Release)
"ANGLE plc...is delighted to announce breakthrough results from DNA molecular analysis of cancer patient blood samples that provide a unique insight into the progression of each patient's cancer and how this may be treated...Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample highlights potential for the Parsortix system to identify key variants (DNA mutations) missed by other approaches to help guide treatment decisions..."
Clinical data
|
Parsortix Liquid Biopsy
5ms
Use of Parsortix system in pre-clinical model unlocks opportunities for drug discovery (ANGLE plc Press Release)
"ANGLE plc...is delighted to announce the publication of breakthrough work by researchers at the University of New Mexico, US, into the role of CTC gene expression in the progression of melanoma brain metastasis. The researchers used the Parsortix system to harvest CTCs for analysis and concluded that '… gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient.'"
Preclinical
|
Parsortix Liquid Biopsy
6ms
ANGLE launches Portrait+ CTC kit at San Antonio Breast Cancer Symposium (ANGLE plc Press Release)
"ANGLE plc...is delighted to announce the launch of its Portrait®+ CTC staining kit at the San Antonio Breast Cancer Symposium (SABCS)...This launch follows extensive development, optimisation and validation of the kit to provide advanced immunofluorescent (IF) staining of CTCs harvested from a patient blood sample by the Parsortix technology."
Launch
|
Parsortix Liquid Biopsy
6ms
DanioCTC: Analysis of Circulating Tumor Cells from Metastatic Breast Cancer Patients in Zebrafish Xenografts. (PubMed, Cancers (Basel))
DanioCTC represents a major step forward in the endeavors to study the dissemination of individual and rare patient-derived CTCs, thereby enhancing our understanding of metastatic breast cancer biology and facilitating the development of targeted interventions in MBC. Summary statement: DanioCTC is a novel workflow to inject patient-derived CTCs into zebrafish, enabling studies of the capacity of these rare tumor cells to induce metastases.
Journal • Circulating tumor cells • Tumor cell • Metastases
|
Parsortix Liquid Biopsy
7ms
Trial initiation date • Tumor cell
|
CELLSEARCH® • Parsortix Liquid Biopsy
7ms
Effect of Digoxin on clusters of circulating tumor cells in patients with metastatic breast cancer (DICCT) (SABCS 2023)
DICCT provides the first-in-human proof-of-principle that digoxin induces a partial dissolution of CTC clusters in patients with metastatic breast cancer at drug levels that are safe and well tolerated. Conceptualization of follow-up trials including Na/K-ATPase inhibitors and patient outcome endpoints are underway.
Clinical • Circulating tumor cells • Tumor cell • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
EGFR positive
|
Parsortix Liquid Biopsy
7ms
Mechanical conditioning (MeCo) score is higher in circulating tumor cells (CTCs) compared to primary tumors in early-stage breast cancer and even higher in metastases compared to CTCs in metastatic breast cancer (SABCS 2023)
Our results show that the MeCo score is higher in CTCs compared to PTs and in METs compared to CTCs in early- and late-stage breast cancer, respectively. Therefore, the MeCo score is progressively higher throughout the metastatic cascade in breast cancer. These findings demonstrate that mechanical conditioning is retained during metastatic progression, even as cancer cells transition through the circulation where the initial induction by matrix stiffness is lost.
Circulating tumor cells • Tumor cell • Metastases
|
Parsortix Liquid Biopsy
7ms
Research demonstrates potential of the Parsortix system to support powerful characterisation of CTCs in head and neck cancer (ANGLE plc Press Release)
"ANGLE plc...is pleased to announce the publication of a study using the Parsortix system that sheds new light on the phenotypic characteristics of CTCs in Head and Neck Squamous Cell Carcinoma (HNSCC)...The study, conducted by researchers at the University of Birmingham, UK, demonstrates the feasibility of using mass cytometry, a powerful technique widely used for single cell analysis, for the comprehensive characterisation of CTCs captured by the Parsortix system in HNSCC patients."
Clinical data
|
Parsortix Liquid Biopsy
7ms
EARDIS: Proof-of-concept Study of Blood Markers of Tumor Dissemination in Patients With Versus Without Intestinal Polyps (clinicaltrials.gov)
P=N/A; Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
Trial completion date • Trial primary completion date
|
CXCL12 (C-X-C Motif Chemokine Ligand 12) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CSF2 (Colony stimulating factor 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
Parsortix Liquid Biopsy
8ms
Parsortix system outperforms current laboratory standard for disseminated tumour cell harvest (ANGLE plc Press Release)
"ANGLE plc...announces the publication of a study of disseminated tumour cells (DTCs) in bone marrow from breast cancer patients published in the International Journal of Molecular Sciences...Researchers at the University of Tübingen, Germany, used the Parsortix® system for the isolation and harvest of DTCs from bone marrow samples in 360 breast cancer patients (clinical stages I-IV) and compared results to the standard density centrifugation method for DTC detection."
Clinical data
|
Parsortix Liquid Biopsy
8ms
Parsortix system showcased at 'Advances in Circulating Tumor Cells' conference (ANGLE plc Press Release)
"ANGLE plc...is pleased to announce its participation at the 6th Advances in Circulating Tumor Cells (ACTC) conference held in Greece from 20-23 September 2023...This included the presentation of nine posters showcasing the Parsortix® system in six cancer types across eight independent study centres."
Clinical data
|
Parsortix Liquid Biopsy
8ms
Microfluidic Isolation of Disseminated Tumor Cells from the Bone Marrow of Breast Cancer Patients. (PubMed, Int J Mol Sci)
Our advanced method further presents options for 3D DTC cultures, enabling the individualized testing of targeted therapies for BC patients. In conclusion, we present a novel approach for DTC enrichment, with possibilities for future clinical implications.
Journal • Tumor cell
|
Parsortix Liquid Biopsy
8ms
Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer. (PubMed, Int Rev Cell Mol Biol)
However, mesenchymal CTCs and the Parsortix® PC1 system show promise as alternative detection methods. This chapter offers a comprehensive review of clinical studies on CTCs in breast cancer, emphasizing their prognostic and predictive value in different stages of the disease and provides insights into potential future directions in CTC research.
Journal • Circulating tumor cells • Tumor cell • Metastases
|
CELLSEARCH® • Parsortix Liquid Biopsy
8ms
Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping. (PubMed, Br J Cancer)
We demonstrate mass cytometry allows high-plex proteomic characterisation of CTCs at single-cell resolution and identify common CTC sub-groups with potential for novel biomarker development and immune checkpoint inhibitor treatment stratification.
Journal • Circulating tumor cells • IO biomarker • Tumor cell
|
Parsortix Liquid Biopsy
9ms
CHARTER: Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System (clinicaltrials.gov)
P=N/A; N=100 --> 9 | Trial completion date: Jul 2025 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Aug 2023; Futility (slow enrollment)
Trial completion date • Trial primary completion date • Enrollment change • Trial termination • Tumor cell • Metastases
|
Parsortix Liquid Biopsy
9ms
Analytical performance of the FDA-cleared Parsortix PC1 system. (PubMed, J Circ Biomark)
Average harvest rates using ~20 fixed SKBR3 cells spiked into HV and MBC patient blood samples were 75.0% ± 16.1% (%CV = 22.3%) and 68.4% ± 14.3% (%CV = 21.1%), respectively. These evaluations demonstrate the Parsortix PC1 system linearly and reproducibly harvests tumor cells from blood over a range of 1 to ~100 cells.
Journal
|
Parsortix Liquid Biopsy
9ms
New trial • Tumor cell
|
CELLSEARCH® • Parsortix Liquid Biopsy
10ms
Liquid Biopsy Isolation Of Circulating Tumour Cells From Epithelial Ovarian Cancer Patients And Their Prognostic Significance (ESGO 2023)
Follow up of treatment response, PFS, overall survival and 1 year blood-sampling follow up is currently ongoing to establish the clinical significance of single CTCs and CTC clusters detection in the primary surgery and neoadjuvant setting.Conclusion We report that using ANGLE-Parsortix CTC enrichment, single CTCs and CTC clusters can be isolated from blood in ovarian cancer. CTCs isolated from the ovarian vein during surgery are abundant for the precursor metastasising cells that are CTC-clusters, and may show utility for monitoring treatment response and prognosis in the adjuvant setting.
Clinical • Circulating tumor cells • Liquid biopsy • Tumor cell • Biopsy
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
Parsortix Liquid Biopsy
11ms
Novel method for highly multiplexed gene expression profiling of circulating tumor cells (CTCs) captured from the blood of women with metastatic breast cancer. (PubMed, J Transl Med)
HyCEAD/Ziplex provided sensitive quantification of expression of 72 genes from 20 pg of total RNA from cultured tumor cell lines or from single cultured tumor cells spiked into lysates from Parsortix harvests of HV blood. The HyCEAD/Ziplex platform enables the quantification of selected genes in the presence of residual nucleated blood cells in Parsortix harvests. The HyCEAD/Ziplex platform is an effective tool for multiplexed molecular characterization of mRNA in small numbers of tumor cells harvested from blood.
Journal • Circulating tumor cells • Tumor cell • Metastases
|
Parsortix Liquid Biopsy
11ms
Protocol for a prospective study evaluating circulating tumour cells status to predict radical prostatectomy treatment failure in localised prostate cancer patients (C-ProMeta-1). (PubMed, BMC Cancer)
CTC status may reflect the true potential for PCa metastasis and may predict clinical outcomes better than the current PCa progression risk grading systems. Therefore establishing a robust biomarker for predicting treatment failure in localized high-risk PCa would significantly enhance guidance in treatment decision-making, optimizing cure rates while minimizing unnecessary harm from overtreatment.
Journal • Circulating tumor cells • Tumor cell
|
Parsortix Liquid Biopsy
11ms
CTC-based workflow for dissecting pancreatic cancer heterogeneity at single-cell resolution (EACR 2023)
Subsequently, CTCs were then enumerated and picked as single cells using the ALS CellCelector™ (Sartorius, Germany) into a lysis buffer prepared according to the SMART-Seq3 (SS3) protocol for scRNA-seq.ConclusionThis workflow describes a successful isolation and detection of CTCs that opens new avenues of investigation of tumor heterogeneity. Subsequently, the customized SS3 protocol for scRNA-seq will provide full-length transcriptome coverage that introduces a 5'UMI sequence essential for in-silico isoform assignment and allelic origin determination of individual RNAs in single cells.
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CAPRIN1 (Cell Cycle Associated Protein 1)
|
Parsortix Liquid Biopsy
12ms
Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer. (PubMed, Int J Mol Sci)
A tailored PCa gene panel allowed us to stratify metastatic castration-resistant prostate cancer (mCRPC) patients with clinical outcomes. In addition, our findings suggest that targeted CTC transcriptome profiling may be predictive of therapy response.
Journal • Clinical data • Circulating tumor cells • Tumor cell • Metastases
|
CELLSEARCH® • Parsortix Liquid Biopsy